CN1712034A - Chinese medicinal composition, preparation and quality control thereof - Google Patents
Chinese medicinal composition, preparation and quality control thereof Download PDFInfo
- Publication number
- CN1712034A CN1712034A CN 200410048087 CN200410048087A CN1712034A CN 1712034 A CN1712034 A CN 1712034A CN 200410048087 CN200410048087 CN 200410048087 CN 200410048087 A CN200410048087 A CN 200410048087A CN 1712034 A CN1712034 A CN 1712034A
- Authority
- CN
- China
- Prior art keywords
- solution
- reference substance
- methanol
- chromatograph
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003908 quality control method Methods 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 title claims description 11
- 239000003814 drug Substances 0.000 claims abstract description 62
- 230000008569 process Effects 0.000 claims abstract description 28
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 20
- 206010022437 insomnia Diseases 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 205
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 165
- 238000012360 testing method Methods 0.000 claims description 158
- 239000013558 reference substance Substances 0.000 claims description 87
- 229960004756 ethanol Drugs 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 60
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 50
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 50
- 239000007788 liquid Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 45
- 238000000605 extraction Methods 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 32
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 32
- 229960003321 baicalin Drugs 0.000 claims description 32
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 29
- 239000000741 silica gel Substances 0.000 claims description 28
- 229910002027 silica gel Inorganic materials 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- 238000004809 thin layer chromatography Methods 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 24
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 23
- 239000003208 petroleum Substances 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 20
- 230000007812 deficiency Effects 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 19
- 238000005303 weighing Methods 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 16
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 15
- 208000011580 syndromic disease Diseases 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 13
- 208000013403 hyperactivity Diseases 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- SQHQDXGIJPHZRZ-AAWDLAKASA-N Jujuboside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 SQHQDXGIJPHZRZ-AAWDLAKASA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- KVKRFLVYJLIZFD-OPGZLHQPSA-N jujuboside A Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%11OC[C@@H](O)[C@H](O)[C@H]%11O)[C@H](O)[C@H](O)[C@H]1O KVKRFLVYJLIZFD-OPGZLHQPSA-N 0.000 claims description 10
- QCLBRNPQMDEDIM-UHFFFAOYSA-N jujuboside C Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 QCLBRNPQMDEDIM-UHFFFAOYSA-N 0.000 claims description 10
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 8
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 8
- 235000012141 vanillin Nutrition 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 7
- 206010039897 Sedation Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- -1 reflux Substances 0.000 claims description 7
- 230000036280 sedation Effects 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims description 6
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000012850 discrimination method Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 230000003760 hair shine Effects 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 5
- KXUYYFNHOZRVKP-UHFFFAOYSA-N ethanol;4-hydroxy-3-methoxybenzaldehyde Chemical compound CCO.COC1=CC(C=O)=CC=C1O KXUYYFNHOZRVKP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 239000001117 sulphuric acid Substances 0.000 claims description 5
- 235000011149 sulphuric acid Nutrition 0.000 claims description 5
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 4
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 claims 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims 2
- OBAMWENTFIOOIT-UHFFFAOYSA-N butan-2-one;ethyl acetate Chemical compound CCC(C)=O.CCOC(C)=O OBAMWENTFIOOIT-UHFFFAOYSA-N 0.000 claims 2
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 claims 2
- 238000005201 scrubbing Methods 0.000 claims 2
- 229960000583 acetic acid Drugs 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- 230000003446 memory effect Effects 0.000 claims 1
- 230000007958 sleep Effects 0.000 abstract description 50
- 208000009205 Tinnitus Diseases 0.000 abstract description 2
- 208000002173 dizziness Diseases 0.000 abstract description 2
- 231100000886 tinnitus Toxicity 0.000 abstract description 2
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 238000004886 process control Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 137
- 239000002775 capsule Substances 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 31
- 229940079593 drug Drugs 0.000 description 31
- 239000002244 precipitate Substances 0.000 description 27
- 230000005059 dormancy Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- 230000009182 swimming Effects 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 229960002275 pentobarbital sodium Drugs 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 238000011552 rat model Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- KIBLEPZGKRYXBB-UHFFFAOYSA-N butan-2-one ethyl acetate formic acid hydrate Chemical compound O.OC=O.CCC(C)=O.CCOC(C)=O KIBLEPZGKRYXBB-UHFFFAOYSA-N 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010003084 Areflexia Diseases 0.000 description 3
- IBPFZCOJYVDKGN-UHFFFAOYSA-N OC.OC=O.ClC(Cl)Cl.CCOC(C)=O Chemical compound OC.OC=O.ClC(Cl)Cl.CCOC(C)=O IBPFZCOJYVDKGN-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating insomnia, disturbed sleep, dizziness, tinnitus, fidget, etc is prepared from 6 Chinese-medicinal materials including coptis root, rehmannia root, white peony root, wild jujube kernel, etc. Its preparing process and quality control method are also disclosed.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof and method of quality control, particularly a kind of Chinese medicine composition that is used for the treatment of diseases such as the insomnia of syndrome of hyperactivity of fire due to deficiency of YIN finding, dreaminess and preparation method thereof and method of quality control.
Background technology
Motherland's medical science often claims insomnia to be " being insomnia ".Should at first distinguish deficiency and excess clinically, deficiency syndrome belong to deficiency of YIN-blood more, focus on heart spleen Liver and kidney; Excess syndrome is many because of pathogenic fire derived from stagnation of liver-QI, dyspepsia and retention of phlegm, and hyperactivity of heart-fire, in the treatment, its deficiency of nourishing for deficiency; The suitable reducing for the excess syndrome of reality person.Simulataneous insufficiency and excessive person when dividing the specimen weight, sets upright with eliminating evil again.
Insomnia often shows as three kinds of situations clinically, and the one, be difficult to fall asleep; The 2nd, be easy to wake up with a start; The 3rd, be shorter than normally (early awakening) length of one's sleep, or insomnia-middle.How inequality the characteristics of its insomnia of deficiency syndrome excess syndrome are.The fire derived from stagnation of liver-QI type of excess syndrome is because feelings will is not smooth, mechanism of qi retardance, and strongly fragrant and fire-transformation, fire is disturbed the mind and is caused, and shows as insomnia more, dreaming often and waking easily.The type of disturbing is because eating and drinking without temperance on the expectorant heat, and dyspepsia is stagnated, and leads to expectorant heat, disorder of stomach-QI, and disturbing the mind upwards and causing shows as sleep disorder more, sleeps less promptly to wake up or lie awake all night.Type of hyperactivity of heart-fire is that visceral-qi is become estranged owing to overaction of the five emotions, hyperactivity of heart-fire, and refreshing uneasiness is given up and is caused, and shows as more and ponders over dreaminess, dysphoria and insomnia.
The type of deficiency of both the heart and spleen of deficiency syndrome is because overstrain is pondered over too, injures heart spleen, blood failing to tonify the heart, mental derangement and causing.Show as dreaming often and waking easily more, like dream like waking up or sleeplessness whole night.Deficiency of YIN liver-fire type is because plain body innate deficiency, or excess of sexual intercourse, or obstinate disease causes the kidney yin consumption to be hindered, the not good fire of water, and heart-yang is solely high, shows as vexedly to sleep less more, and sleep slightly and promptly wake up, or emission.Type of failure of the heart and kidney integrating is that flaming of heart-fire in the interior can not meet at kidney down owing to overaction of the five emotions; Or various reasons causes kidney yin consumption to be hindered, hyperaction of mingmen fire, and heart monarch is disturbed and cause, show as fidgets due to deficiency and be insomnia, difficulty falling asleep is slept slightly and is promptly waken up, or nocturnal emission is arranged, and many body constitution of type of deficiency of heart-QI and gallbladder-QI weakness, heart and gallbladder is plain empty, frightened cruelly, undermine heart and gallbladder, refreshing uneasy the Tibetan, resolution is had no right and is caused, show as insomnia and dreamful sleep, in time, easily wake up with a start.
Syndrome of hyperactivity of fire due to deficiency of YIN is seen insomnia clinically, mainly is because deficiency of kidney-YIN, due to the hyperactivity of heart-fire, should focus on restoring normal coordination between the heart and kidney in the treatment, thereby the kidney invigorating water, clearing away liver-fire, falls heart-fire and reach regulation between water and fire, the effect of sleeping peacefully of YIN and YANG balancing.Fully excavate the rich experiences of diseases such as the insomnia of Chinese medicine syndrome of hyperactivity of fire due to deficiency of YIN finding, dreaminess, in conjunction with research and the Chinese medicine latest developments of modern medicine to primary disease, the Chinese patent medicine of diseases such as the treatment syndrome of hyperactivity of fire due to deficiency of YIN finding insomnia that develop a kind of determined curative effect, cheap, suitable China's national situation, carry taking convenience, has no side effect, dreaminess has important theoretical meaning and value for clinical application.
Summary of the invention
One object of the present invention is to disclose a kind of Chinese medicine composition; Another object of the present invention is to disclose a kind of Chinese medicine composition that is used for the treatment of diseases such as the insomnia of syndrome of hyperactivity of fire due to deficiency of YIN finding, dreaminess; The 3rd purpose of the present invention is to disclose a kind of preparation method of Chinese medicine composition; The object of the invention also is to disclose a kind of method of quality control of Chinese medicine composition.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Rhizoma Coptidis 30-60 weight portion Radix Rehmanniae 200-250 weight portion Radix Scutellariae 120-150 weight portion
Radix Paeoniae Alba 200-250 weight portion Fructus Schisandrae Chinensis 120-150 weight portion Semen Ziziphi Spinosae 400-500 weight portion
It is (by weight) that the crude drug of pharmaceutical composition of the present invention is formed optimum ratio:
Rhizoma Coptidis 45 weight portion Radix Rehmanniae 225 weight portion Radix Scutellariaes 135 weight portions
The Radix Paeoniae Alba 225 weight portion Fructus Schisandrae Chinensis 135 weight portion Semen Ziziphi Spinosae (parched)s 450 weight portions
It is (by weight) that the crude drug of pharmaceutical composition of the present invention is formed optimum ratio:
Rhizoma Coptidis 35 weight portion Radix Rehmanniae 245 weight portion Radix Scutellariaes 125 weight portions
The Radix Paeoniae Alba 245 weight portion Fructus Schisandrae Chinensis 125 weight portion Semen Ziziphi Spinosaes 480 weight portions
It is (by weight) that the crude drug of pharmaceutical composition of the present invention is formed optimum ratio:
Rhizoma Coptidis 55 weight portion Radix Rehmanniae 210 weight portion Radix Scutellariaes 145 weight portions
The Radix Paeoniae Alba 205 weight portion Fructus Schisandrae Chinensis 145 weight portion Semen Ziziphi Spinosae (parched)s 420 weight portions
This preparation of drug combination method:
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 6-10 and doubly measure 60-80% ethanol, reflux, extract, 1-3 time, and each 1-2 hour, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 8-12 times of water gaging, decoct each 1-3 hour 1-3 time, gradation filters, merging filtrate, and being concentrated into relative density 60 ℃ of filtrates is 1.10 clear paste, add ethanol and make and contain alcohol amount and reach 50-60%, stir evenly cold preservation 24 hours, filter, reclaim ethanol, be condensed into thick paste, be dried to driedly, be ground into fine powder, merge above-mentioned two kinds of fine powders, get this pharmaceutical composition, this pharmaceutical composition can be made into clinical acceptable forms, comprises tablet, capsule, granule etc.
Selecting micropowder silica gel and dextrin is molding adjuvant of the present invention, and usage ratio is dextrin: micropowder silica gel=1-3: 2-5.
The method of quality control of this composite preparation contains one or more in following discriminating and/or the content assaying method, and discriminating in the method for quality control of the present invention and content assaying method are:
Discrimination method is selected from one or more in the following method:
A, get content 1g of the present invention, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 20-40 minute, filter, filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (11-13: 5-7: 2-4: 2-4: 1-2) be developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
B, get the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with ethyl acetate-butanone-formic acid-water (4-6: 2-4: 1-2: 1-2) be developing solvent, launch, take out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get content 6g of the present invention, add 60～90 ℃ petroleum ether 30ml, reflux 20-40 minute, filter, medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, (12-18: 4-6: upper solution 1-2) is developing solvent with petroleum ether-Ethyl formate of 60-90 ℃-formic acid, launch, take out, dry, put under the ultra-violet lamp (254nm) and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D, get under the c item medicinal residues behind 60-90 ℃ the Petroleum ether extraction, volatilize petroleum ether, put in the tool plug conical flask, add methanol 40ml, close plug supersound process 20-40 minute, filters, the filtrate evaporate to dryness, residue adds water 30ml makes dissolving, filters, and filtrate moves in the separatory funnel, add water saturated n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, and the ammonia (40ml strong aqua ammonia thin up to 100ml) saturated with n-butyl alcohol washs 3 times, each 10ml, discard washing liquid, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds dehydrated alcohol 2ml makes dissolving, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (30-50: 4-6: 8-12: 0.1-0.3) be developing solvent, launch, take out, dry, spray is with 5% vanillin sulphuric acid liquid, and it is clear to be heated to the speckle colour developing; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
E, get jujuboside A reference substance, add dehydrated alcohol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of jujuboside A reference substance solution under the d item, put respectively on same silica gel g thin-layer plate, (3-5: 1-2: upper strata liquid 4-6) is developing solvent with n-butyl alcohol-glacial acetic acid-water, launch, take out, dry, spray is with vanillin ethanol solution of sulfuric acid (get vanillin 2g add 10% ethanol solution of sulfuric acid 100ml dissolving), and it is clear to be heated to the speckle colour developing at 100 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Content assaying method is:
Measure according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D).
With octadecylsilane chemically bonded silica is that potassium dihydrogen phosphate-acetonitriles filler: 0.05mol/L, 47: 53 are mobile phase, and wherein every 1000ml mobile phase contains sodium lauryl sulphate 1.7g; The detection wavelength is 265nm; Number of theoretical plate calculates by the berberine hydrochloride peak should be not less than 4000; It is an amount of that precision takes by weighing the berberine hydrochloride reference substance, uses 50% dissolve with methanol, makes the solution that every 1ml contains 0.025mg, shakes up, and promptly gets reference substance solution; Get the content under the content uniformity, porphyrize is got about 0.3g, the accurate title, decide, and puts in the tool plug conical flask, the accurate 50% methanol 50ml that adds, claim to decide weight, reflux 20-40 minute, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with 50% methanol, filter, get subsequent filtrate, filter, promptly get need testing solution with microporous filter membrane (0.45 μ m); Accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure, and every of this product contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 1.0mg.
Pharmaceutical composition mind calming of the present invention liver heat removing, nourishing YIN and benefiting blood is held back god and is slept peacefully.Cure mainly the insomnia of syndrome of hyperactivity of fire due to deficiency of YIN finding, vexed, dreaminess, dizziness and tinnitus, dry mouth and throat, diseases such as dysphoria with feverish sensation in the chest palms and soles.The preparation stabilization that the present invention realizes, quality controllable.
Press 0.984g crude drug/kg, 2.952g crude drug/kg and 8.856g crude drug/kg with capsule (sleep and the consider the peace capsule) rat that the present invention makes, mice presses 1.422g crude drug/kg, 4.265g crude drug/kg and 12.794g crude drug/kg (presses body surface area calculating, be equivalent to 1,3 and 9 times clinical people every day with the 10.935g crude drug) oral administration, result of the test is as seen: sleep consider that the peace capsule obviously prolongs stagnation of liver-QI rat model, insufficiency of heart-QI mice and pentobarbital sodium collaborative length of one's sleep, suspension transfixion time, forced swimming dead time, and can improve the memory of rat model; Also obviously prolong normal mouse and pentobarbital sodium and work in coordination with the length of one's sleep, hang quiescent time, forced swimming dead time, and can reduce autonomic activities; Can also suppress normal rat and seize the sexual assault behavior.Illustrating that the worry peace capsule of sleeping has the effect that the mind calming liver heat removing is calmed the nerves, and has the good curing effect to the insomnia.Following experimental example is used to further specify the present invention:
Experimental example 1 Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis alcohol extraction technology are investigated
1, alcohol extraction interference experiment test method
Take by weighing with batch medical material by table 1, add 10 times of amount 70% ethanol respectively, extract 2 times, each 2 hours, merge pure liquid, concentrate, be settled to 1000ml with 70% ethanol, be equipped with inspection.
The table 1 alcohol extraction interference experiment medical material amount of taking by weighing (g)
| Tested number | The medical material amount |
| ??1 ??2 ??3 | Rhizoma Coptidis 30g Rhizoma Coptidis 30g+ Radix Paeoniae Alba 50g Rhizoma Coptidis 30g+ Radix Paeoniae Alba 50g+ Fructus Schisandrae Chinensis 50g |
Adopt high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D) to measure berberine hydrochloride; Chromatographic condition: OPS-C18 post; Mobile phase: acetonitrile: 0.05mol/LKH2P04 (transferring PH=5.0)=28: 72 with 10%KOH, column temperature: room temperature: detect wavelength: 265nm; Flow velocity: 1.0ml/min.The preparation of reference substance solution: precision takes by weighing berberine hydrochloride 5mg after drying, puts to add methanol in the 50ml measuring bottle and be diluted to scale, shakes up, promptly.The preparation of need testing solution: the accurate sample solution 2ml that draws, put in the 25ml measuring bottle, add 50% methanol and be diluted to scale, shake up, promptly.The preparation of Rhizoma Coptidis medical material solution: precision takes by weighing Rhizoma Coptidis medicinal powder 0.3062g, puts in the 500ml round-bottomed flask, adds 50ml methanol, connect apparatus,Soxhlet's and be extracted into colourlessly, filter, and with an amount of methanol wash filtering residue and container, filtrate is transferred in the 50ml volumetric flask, to scale, shake up the accurate 2ml that draws with methanol constant volume, put in the 5ml volumetric flask,, shake up to scale with methanol constant volume, promptly.Measure: accurate respectively reference substance solution and the need testing solution drawn, each 10ul of Rhizoma Coptidis medical material solution injects chromatograph of liquid respectively, measures in accordance with the law, and Rhizoma Coptidis medical material content of berberine hydrochloride is 6.2%, and interference test the results are shown in Table 2.
Table 2 interference test berberine hydrochloride extracted amount
| Tested number | Berberine hydrochloride extracted amount (mg) | The berberine hydrochloride rate of transform (%) |
| ??1 ??2 ??3 | ??1784.5 ??1758.5 ??1769.1 | ??95.49 ??94.54 ??95.11 |
The above results shows Rhizoma Coptidis and the Radix Paeoniae Alba, the common alcohol extraction of Fructus Schisandrae Chinensis, disturbs lessly, can carry altogether.For preferred each parameter of alcohol extraction process better, adopt the orthogonal experiment test.
2, alcohol extraction process orthogonal test
The factor that influences alcohol extraction process mainly contains the ethanol multiple, concentration of alcohol, extraction time, extraction time four factors, adopt L9 (34) table to carry out, if four factors are all included in, then there is not error term, can have influence on the reliability of result of the test, if design error item, adopt L18 (37) orthogonal table, test number (TN) is too many, considers that the alcohol extraction number of times generally adopts 2 times in the industrialized great production, with reference to aforementioned interference test, extract 2 times, extraction efficiency is very high, for this reason the fixed extraction number of times, adopt the test of L9 (34) orthogonal table, can further investigate the feasibility of extraction time simultaneously in the preferred back of orthogonal test.So the design factor water-glass is as follows:
Table 3 alcohol extraction process orthogonal test factor level table
| Horizontal factor | Concentration of alcohol (%) | Ethanol multiple (doubly) | Extraction time (hour) |
| ??1 ??2 ??3 | ??60 ??70 ??80 | ??6 ??8 ??10 | ??1 ??1.5 ??2 |
Take by weighing Rhizoma Coptidis 30g, totally 9 parts of Radix Paeoniae Alba 150g, Fructus Schisandrae Chinensis 90g, by orthogonal table L9 (34) test, every part of heating and refluxing extraction 2 times, merge extractive liquid, is concentrated into 100ml, is equipped with inspection.Adopt the content of high effective liquid chromatography for measuring berberine hydrochloride, condition, the same interference test of method; The preparation of need testing solution: get above-mentioned concentrated solution, shake up, supersound process 5 minutes, the accurate absorption extracted concentrated solution 1ml, and it is little to put the 50ml volumetric flask,, shakes up to scale with 50% methanol constant volume, promptly.Orthogonal test and result of the test see Table 4.
Table 4 orthogonal test and result of the test
| Tested number | Concentration of alcohol (A) | Ethanol multiple (B) | Extraction time (C) | ??D | Berberine hydrochloride extracted amount (mg) |
| ??1 ??2 ??3 ??4 ??5 ??6 ??7 ??8 ??9 | ?1(60％) ?1 ?1 ?2(70％) ?2 ?2 ?3(80％) ?3 ?3 | 1 (6 times) 2 (8 times), 3 (10 times) 123123 | 3 (2 hours) 231312,1 (1 hour) 2 (1.5 hours) | ??1 ??2 ??3 ??3 ??1 ??2 ??2 ??3 ??1 | ??1459.00 ??1365.81 ??1572.34 ??1413.89 ??1836.15 ??1519.72 ??1565.88 ??1332.61 ??1344.99 |
| ??K1 ??K2 ??K3 ??K1/3 ??K2/3 ??K3/3 ??R | ?4397.15 ?4769.76 ?4243.48 ?1465.72 ?1589.92 ?1414.49 ?175.49 | ?4438.77 ?4534.57 ?4437.05 ?1479.59 ?1511.52 ?1479.02 ?32.50 | ??4311.33 ??4124.69 ??4974.37 ??1437.00 ??1374.90 ??1658.12 ??283.22 | ??4640.14 ??4451.41 ??4381.84 ??1546.71 ??1483.80 ??1439.61 ??136.54 | ??T＝13410.39 ??CT＝T 2/9＝19982062 |
With R value intuitive analysis Rc＞RA＞RD＞RB, visible C factor affecting maximum, B factor affecting minimum, and it is optimum level that A2＞A1＞A3, B2＞B1＞B3, C3＞C2＞C1 should select A2B2C3, in order to optimize technological parameter better, The above results is carried out variance analysis, the results are shown in Table 5.
Table 5 alcohol extraction orthogonal test analysis of variance table
| Soruces of variation | Sum of sguares of deviation from mean | Degree of freedom | Mean square | The F value | Significance |
| ??A ??e＝B ??C ??D | ??48824.81 ??2076.74 ??132934.74 ??17380.83 | ??2 ??2 ??2 ??2 | ??24412.41 ??1038.37 ??66467.37 ??8690.42 | ??23.51 ??64.01 ??8.37 | ??＜0.05 ??＜0.05 ??＞0.05 |
Fa＝0.01(2，2)＝99.0??????Fa＝0.05(2，2)＝19
From last table as seen, B factor sum of sguares of deviation from mean minimum is carried out variance analysis with it as error term for this reason, Table A, each level of C factor have significant difference as a result, so select optimum level A2C3, the B factor can be chosen a level wantonly because of there was no significant difference, both considered operability in the production, consider again and save the cost and the energy, choose B2, promptly choose and use 70% ethanol, 8 times of amounts are extracted 2 times, and each 2 hours is alcohol extraction process.
3, the checking of alcohol extraction process
Because extraction time is a fixed factor in orthogonal test, do not carry out preferably, whether feasible, remain further to be verified.
Take by weighing two parts of Rhizoma Coptidis 30g, Radix Paeoniae Alba 150g, Fructus Schisandrae Chinensis 90g, carry out alcohol extraction by above-mentioned selection process respectively, merge pure liquid, medicinal residues continue to extract 2 hours with 8 times of amount 70% ethanol, and each 100ml that takes a sample detects, testing conditions and method are the same, being prepared as of need testing solution: preceding 2 extracting solution, the accurate 5ml that draws, put in the 25ml measuring bottle, add 50% methanol constant volume to scale, shake up, that is: the 3rd extracting solution, filter, promptly.Testing result sees Table 6.
Table 6 alcohol extraction demonstration test result
| Tested number | Preceding 2 berberine hydrochloride extracted amounts (mg) | Extraction ratio (%) | The 3rd berberine hydrochloride extracted amount (mg) | Extraction ratio (%) |
| ??1 ??2 | ??1772.74 ??1769.00 | ??95.31 ??95.11 | ?101.34 ?86.13 | ??5.45 ??4.63 |
From the last table average extraction rate reached 95% of can seing before 2 times, the basic extraction fully, the 3rd time extraction ratio only is about 5%, and has rolled up man-hour and production cost, to extract 2 times be feasible so adopt.According to above-mentioned result of the test, alcohol extraction process is defined as: add 8 times of amount 70% ethanol, extract 2 times, each 2 hours, gradation filtered, and merges pure liquid.
Experimental example 2 alcohol extract ethanol reclaim, and concentration process is to the influence of content of berberine hydrochloride
In order to consider the influence of berberine hydrochloride at ethanol recovery and concentration process, alcohol extract that will be in confirmatory experiment, last pure liquid after sampling 100ml check, decompression recycling ethanol, and be concentrated into certain volume, get thick paste, sampling, measure content of berberine hydrochloride, the same interference test of assay method and condition.The preparation of need testing solution: precision is measured concentrated solution 1ml, puts in the 50ml measuring bottle, adds 50% methanol to scale, shakes up, promptly.Result of the test sees Table 7.
Table 7 alcohol extract ethanol reclaims, and concentration process is to the influence of content of berberine hydrochloride
| Tested number | Alcohol liquid long-pending (ml) | Berberine hydrochloride amount (mg) | Thick paste volume (ml) | Berberine hydrochloride amount (mg) | Retention rate (%) |
| ??1 ??2 | ??3287 ??3385 | ??1720.40 ??1718.24 | ??245 ??290 | ??1612.11 ??1624.96 | ??93.71 ??94.57 |
From the average retention rate of the visible berberine hydrochloride of last table result ethanol recovery and concentration process is 94.14%; Illustrate that this process is less to the influence of berberine hydrochloride, on producing, adopt decompression recycling ethanol and high-efficiency evaporator to concentrate feasible.
Experimental example 3 alcohol extract thick paste dry runs are to the influence of berberine hydrochloride
After above-mentioned concentrated thick paste sampling, get 200ml respectively, put (85 ± 2 ℃ in electrically heated drying cabinet (85 ± 2 ℃) and vacuum drying oven,-0.1MPa) be dried to driedly, take by weighing weight, the sampling and measuring content of berberine hydrochloride, the same interference test of condition determination and method. need testing solution is prepared as: precision takes by weighing dried cream powder end 0.6g, add 50% methanol 50ml, supersound process 30min filters, precision is measured in subsequent filtrate 10ml to the 25ml measuring bottle, add 50% methanol constant volume to scale, shake up, promptly.Result of the test sees Table 8.
Table 8 alcohol extract thick paste in dry run to the influence of berberine hydrochloride
| Tested number | Drying mode | Thick paste volume (ml) | Berberine hydrochloride amount (mg) | Dried cream amount (mg) | Berberine hydrochloride amount (mg) | Retention rate (%) |
| ??1 ??2 | The direct heat drying vacuum drying | ??200 ??200 | ??1316.01 ??1120.66 | ??58 ??43 | ??1245.46 ??1076.03 | ??94.64 ??96.02 |
From last table as seen, dry run is less to the content of berberine hydrochloride influence, adopts direct heat drying and vacuum drying difference little, produces and can select drying room drying and vacuum drying according to manufacturing enterprise's physical condition.
The investigation of experimental example 4 Radix Scutellariaes, Radix Rehmanniae, Semen Ziziphi Spinosae (parched) extraction process by water
1, for the extraction process by water manufacturing parameter of preferred Radix Scutellariae, Radix Rehmanniae, Semen Ziziphi Spinosae (parched) better, adopt the orthogonal experiment test, select orthogonal table L9 (34) for use, the investigation index is a content of baicalin.Take by weighing Radix Scutellariae 45g, Radix Rehmanniae 75g, Semen Ziziphi Spinosae (parched) 150g, nine parts, soak after 1 hour earlier and test by the orthogonal table tested number, merge extractive liquid, suitably is concentrated into 200ml, and cold preservation is equipped with inspection.
2, content of baicalin assay method
Record radix scutellariae medicinal materials content of baicalin assay method with reference to Chinese Pharmacopoeia, adopt high performance liquid chromatography (2000 editions one appendix VI D of Chinese Pharmacopoeia) to measure.Chromatographic condition: ODS-C18 post, mobile phase: methanol-water-phosphoric acid (47: 53: 0.2); Column temperature: room temperature, detect wavelength: 280mm flow velocity: 1.0ml/min.The preparation of reference substance solution: precision takes by weighing and adds methanol in right amount through 4 hours baicalin reference substance of 60 ℃ of drying under reduced pressure and make the solution that every 1ml contains 60 μ g, promptly.The preparation of need testing solution: get concentrated solution, jolting, supersound process 10 minutes makes mixing, and precision is measured 1ml, puts in the 100ml measuring bottle, adds 70% ethanol and is settled to scale, shakes up, and precision is measured 2ml, puts in the 10ml measuring bottle, adds methanol constant volume to scale, shakes up, promptly.Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, calculate, promptly.Orthogonal test and result see Table 9
Water such as table 9 Radix Scutellariae are put forward orthogonal experiments
| Tested number | Add water multiple (A) | Decoct number of times (B) | Decocting time (C) | ??D | Baicalin extracted amount (mg) |
| ??1 ??2 ??3 ??4 ??5 ??6 ??7 ??8 ??9 | 1 (8 times) 112 (10 times), 223 (12 times) 33 | 1 (1 time) 2 (2 times), 3 (3 times) 123123 | 3 (3 hours) 231312,1 (1 hour) 2 (2 hours) | ??1 ??2 ??3 ??3 ??1 ??2 ??2 ??3 ??1 | ??1229 ??2258 ??2298 ??1531 ??2038 ??2195 ??1712 ??1866 ??2267 |
| ??K1 ??K2 ??K3 ??K1/3 ??K2/3 ??K3/3 ??R | ??5785 ??5764 ??5845 ??1928 ??1921 ??1948 ??27 | ??4472 ??6162 ??6760 ??1491 ??2054 ??2253 ??762 | ??5290 ??6056 ??6048 ??1763 ??2019 ??2016 ??256 | ??5534 ??6165 ??5695 ??1845 ??2055 ??1892 ??210 | ??T＝17394 ??CT＝T 2/9＝33616804 |
From the intuitive analysis of R value, RB＞RC＞RD＞RA, as seen factor B and C influence is bigger, and factor A influence is less, and A3＞A1＞A3, B3＞B2＞B1, C2＞C3＞C1, should select A3B3C2 is optimum level, in order to optimize technological parameter better, The above results is carried out variance analysis, the results are shown in Table 10.
Water such as table 10 Radix Scutellariae are carried the orthogonal test analysis of variance table
| Soruces of variation | Sum of sguares of deviation from mean | Degree of freedom | Mean square | The F value | Significance |
| ??e＝A ??B ??C ??D | ??1178 ??938739 ??129043 ??71665 | ??2 ??2 ??2 ??2 | ??589 ??469369.5 ??64521.5 ??35832.5 | ??796.9 ??109.5 ??60.5 | ??＜0.01 ??＜0.01 ??＜0.05 |
Fa＝0.01(2，2)＝99.0?????Fa＝0.05(2，2)＝19
From the mean square minimum of the visible A factor of last table,, select A1 because of there was no significant difference from producing using water wisely and reducing energy consumption consideration A factor so with it as error term relatively, the result shows that B, C all have utmost point significant difference, should choose optimum level B3C2.Promptly choose and add 8 times of water gagings decoctions 3 times, each 2 hours.
Because above-mentioned orthogonal test B, C factor have utmost point significant difference, be necessary orthogonal experiments is carried out demonstration test, investigate the baicalin rate of transform, to judge the reliability of technological parameter.Test method: take by weighing totally 3 parts of Radix Scutellariae 90g, Radix Rehmanniae 150g, Semen Ziziphi Spinosae (parched) 300g, add 8 times of water gagings respectively, decoct 3 times, each 2 hours, filter respectively, merging filtrate shakes up, and measures volume, and each 200ml cold preservation of taking a sample is equipped with inspection.Content assaying method is with aforementioned baicalin condition determination method.The preparation of test solution: get extracting solution, shake up, supersound process 10 minutes, the accurate 1ml that draws puts in the 25ml measuring bottle,, shakes up to scale with methanol constant volume, promptly.The preparation of radix scutellariae medicinal materials solution: precision takes by weighing decides medical material fine powder 0.3g, adds 70% methanol 40ml, reflux 3 hours, filter, filtrate is to the 100ml measuring bottle, and with a small amount of 70% ethanol gradation washing container and residue, washing liquid is filtered in the measuring bottle, add 70% ethanol and be settled to scale, shake up, the accurate 1ml that draws puts in the 10ml measuring bottle, adds methanol constant volume to scale, shake up, promptly.Measurement result: radix scutellariae medicinal materials, content of baicalin is 14.32%, water is put forward the rate of transform and be the results are shown in Table 11.
Table 11 Radix Scutellariae water is put forward the demonstration test result
| Tested number | Extracting liquid volume (ml) | Baicalin extracted amount (mg) | The baicalin rate of transform (%) |
| ??1 ??2 ??3 | ??9350 ??8530 ??9680 | ??11713.06 ??11633.61 ??11189.54 | ??90.88 ??90.27 ??86.92 |
Above result shows, and is higher by the preferred extraction process by water of orthogonal test, baicalin mean transferred rate, about 90%, can adopt this technology to carry out water and carry.
The investigation of experimental example 5 Radix Scutellariae water extracting liquid precipitate with ethanol processes
In order to reach purified purpose, reduce the single dose, adopt the alcohol deposition method roguing, adopt the preferred precipitate with ethanol technological parameter of orthogonal experiment.The factor that influences the precipitate with ethanol process is mainly the relative density of concentrated solution, and alcohol precipitation concentration and precipitate with ethanol time serve as to investigate index with the retention rate of baicalin, and the factor level table sees Table 12.
Table 12 precipitate with ethanol orthogonal test factor level table
| Horizontal factor | Relative density | Alcohol precipitation concentration (%) | The precipitate with ethanol time (hour) |
| ??1 ??2 ??3 | (1.10 60 ℃ of heat are surveyed) 1.15 1.20 | ??60 ??70 ??80 | ??12 ??24 ??36 |
The concentrated solution sample 1 (d=1.10) of water extract concentration processs such as above-mentioned Radix Scutellariae being investigated test divides 3 parts, every part of 200ml, and concentrated solution sample 2 (d=1.15) divides 3 parts, every part of 150ml, concentrated solution sample 3 (d=1.20) divides 3 parts, every part of 100ml, choose concentrated solution by the corresponding relative density of the tested number of orthogonal test table, test by tested number, behind the precipitate with ethanol, divide and get upper strata liquid, subnatant filters, filtrate and upper strata liquid merge, and sampling is equipped with inspection.
1, content of baicalin assay method
Adopt high effective liquid chromatography for measuring, condition and method are the same, the preparation of need testing solution: the pure liquid 1ml of accurate absorption, put in the 50ml measuring bottle, and add methanol constant volume to scale, shake up, promptly.
2, orthogonal test and result of the test see Table 13.
Table 13 orthogonal test and result
| Tested number | Relative density (A) | Alcohol precipitation concentration (B) | The precipitate with ethanol time (C) | ??D | Baicalin retention rate (%) |
| ??1 ??2 ??3 ??4 ??5 ??6 ??7 ??8 ??9 | ??1(1.10) ??1 ??1 ??2(2.15) ??2 ??2 ??3(1.20) ??3 ??3 | ??1(60％) ??2(70％) ??3(80％) ??1 ??2 ??3 ??1 ??2 ??3 | 3 (36 hours) 231312,1 (12 hours) 2 (24 hours) | ??1 ??2 ??3 ??3 ??1 ??2 ??2 ??3 ??1 | ??78.97 ??60.90 ??38.20 ??59.65 ??44.64 ??29.91 ??32.46 ??25.32 ??15.82 |
| ??K1 ??K2 ??K3 ??K1/3 ??K2/3 ??K3/3 ??R | ??178.07 ??134.20 ??73.60 ??59.36 ??44.73 ??24.53 ??34.83 | ??171.08 ??130.86 ??83.93 ??57.03 ??43.33 ??27.98 ??29.05 | ??134.20 ??136.37 ??115.30 ??44.73 ??45.46 ??38.43 ??7.03 | ??139.43 ??123.27 ??123.17 ??46.48 ??41.09 ??41.06 ??5.42 | ??T＝385.87 ??CT＝T 2/9＝16543.96 |
Visible RA＞the RB of intuitive analysis The above results＞RC＞the RD explanation influences baicalin rate of transform A＞B＞C, and A1＞A2＞A3, B1＞B2＞B3, and C2＞C1＞C3, optimum level is A1B1C2 for this reason.In order further to analyze each factor affecting degree, The above results is carried out variance analysis, the results are shown in Table 14.
The variance analysis of table 14 orthogonal test
| Soruces of variation | Sum of sguares of deviation from mean | Degree of freedom | Mean square | The F value | Significance |
| ??A ??B ??C ??e＝D | ??1834.54 ??1268.36 ??89.54 ??58.40 | ??2 ??2 ??2 ??2 | ??917.27 ??634.18 ??44.77 ??29.20 | ??31.41 ??21.72 ??1.53 | ??＜0.05 ??＜0.05 ??＞0.05 |
Fa＝0.01(2，2)＝99.0??????Fa＝0.05(2，2)＝19
Last table result shows that A, B factor all have significant difference, should choose optimum level first level, and simultaneously from precipitate with ethanol process retention rate, precipitate with ethanol is bigger to the baicalin influence.
3, test of precipitate with ethanol process verification and elongation test
Take by weighing Radix Scutellariae 90g, Radix Rehmanniae 150g, Semen Ziziphi Spinosae (parched) 300g, totally two parts, extract by extraction process by water respectively, extracting solution is concentrated into d=1.10 (60 ℃ of heat are surveyed) and measures volume, be respectively 700ml, 625ml, sampling is got 300ml2 part with the 1st part of concentrated solution after detecting, and carries out the precipitate with ethanol test by table 12-17 test 1 and 2, the 2nd part of concentrated solution got 300ml carry out the precipitate with ethanol test by table 12-17 test 3, get 250ml and adjust volume to being 1.05 to relative density, measuring volume is 580ml, carries out the precipitate with ethanol test by table 15 test 4, branch was got supernatant after each tested precipitate with ethanol, subnatant filters, and filtrate and supernatant merge, and measure volume, sampling detects, detection method and condition are the same, and extension rate is done suitable adjustment as required in the preparation process of test liquid, and result of the test sees Table 16.
Table 15 precipitate with ethanol demonstration test parameter
| Tested number | Concentrate liquid measure (ml) | Relative density | Alcohol precipitation concentration (%) | The precipitate with ethanol time (h) |
| ??1 ??2 ??3 ??4 | ??300 ??300 ??300 ??580 | ??1.10 ??1.10 ??1.10 ??1.05 | ??60 ??50 ??60 ??60 | ??24 ??24 ??24 ??24 |
Table 16 precipitate with ethanol demonstration test result
| Tested number | The precipitate with ethanol effect | Content of baicalin (mg) before the precipitate with ethanol | Content of baicalin behind the precipitate with ethanol (mg) | Retention rate (%) |
| ??1 ??2 ??3 ??4 | The interface is clear, it is unclear to filter normal interface, the filtration difficulty interface is clear, it is clear to filter normal interface, filters normal | ??4660.77 ??4660.77 ??5316.83 ??4430.69 | ??3733.8 ??3186.67 ??4651.56 ??3821.93 | ??80.11 ??68.37 ??87.49 ??86.26 |
Adopt 50% alcohol precipitation concentration precipitate with ethanol as seen from Table 16, do not reach the precipitate with ethanol effect, so that filtration difficulty, baicalin is adsorbed in the precipitate, and retention rate is very low, and is infeasible in the production, adopt the d=1.05 precipitate with ethanol, volume is big, and the ethanol consumption is big, and retention rate and d=1.10 are suitable, can not obviously improve retention rate, can not adopt for this reason, and d=1.10,60% alcohol precipitation concentration, retention rate can be greater than 80%, although illustrate that precipitate with ethanol is influential to baicalin,, still can adopt in order to satisfy purified needs.The alcohol precipitation process parameter is defined as for this reason: relative density is that 1.10 (60 ℃ of heat are surveyed) alcohol precipitation concentration is 60%, precipitate with ethanol 24 hours.
The influence of 6 pairs of stagnation of liver-QI rat models of experimental example pentobarbital sodium induced hypnotic time
Getting body weight is 60 of 200～220g male rats, be divided into normal group (waiting capacity) at random, model group (waiting capacity), positive group (8.10g/kg), sleep to consider little (the 0.984g crude drug/kg) of peace, in (the 2.952g crude drug/kg), (the 8.856g crude drug/kg) (press body surface area calculates heavy dose of group, be equivalent to clinical people and use 1 of 10.935g crude drug every day, 3 and 9 times) except that normal group, other are respectively organized rat and clamp afterbody with vascular forceps and enrage rat, make it to keep the fight state with other rats, once a day, each 45min, modeling is 30 days continuously, rat skin lower injection epinephrine 0.2mg/ weekly of while.After the modeling, according to dosage successive administration 4 days (1.0ml/100g body weight) behind last administration 30min, is pressed 40mg/kg lumbar injection pentobarbital sodium, and record rat sleep incubation period and righting reflex loss the results are shown in Table 17 to the length of one's sleep of recovering.
Table 17 sleep to be considered the peace capsule lures the different length of one's sleep to stagnation of liver-QI rat model pentobarbital sodium influence (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Incubation period | The length of one's sleep |
| ??(min) | ??(min) | |||
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 8.10 0.98 2.95 8.86 | ??8.10±3.87 ??10.10±3.31 ??7.00±2.45△ ????6.50±3.50△ ????7.30±2.19△ ????6.70±1.70△ | ??102.70±26.31 ??74.60±16.89** ??120.20±6.05**△△ ????92.70±21.68△ ????124.60±25.40△△ ????221.10±38.21**△△ |
With normal group than * P＜0.05, * * P＜0.01, with model group than △ P＜0.05, △ △ P＜0.01
By table 17 as seen: after the rat modeling, the incubation period and the length of one's sleep obviously shorten, and the modeling success is described.Animal pattern obviously prolongs the length of one's sleep, shortens incubation period after considering the peace capsule with sleeping, and with the model group ratio significant difference is arranged.Illustrating that capsule is pacified in the worry of sleeping and pentobarbital sodium has certain synergism.
The influence of 7 pairs of stagnation of liver-QI rat model memories of experimental example
Screening (time of arriving at platform in Y type water maze the is no more than 15 seconds) body weight of learning from else's experience is 60 of 200～220g rats, be divided into normal group (waiting capacity) at random, model group (waiting capacity), positive group (8.10g/kg), sleep to consider little (the 0.984g crude drug/kg) of peace, in (the 2.952g crude drug/kg), (the 8.856g crude drug/kg) (press body surface area calculates heavy dose of group, be equivalent to clinical people and use 1 of 10.935g crude drug every day, 3 and 9 times) the modeling administration is the same, and 24h trains twice in Y type water maze continuously before the last administration, 30min behind the last medicine measures the time that rat is correctly arrived at platform of respectively organizing.The results are shown in Table 18.
The influence that table 18 dormancy worry peace capsule is remembered the stagnation of liver-QI rat model (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Arrive at the platform time (s) |
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 8.10 0.98 2.95 8.86 | ??8.60±2.67 ??11.60±2.95* ??8.90±2.85△ ????10.60±2.55 ??9.40±2.11 ??8.30±2.41△△ |
With normal group than * P＜0.05, * * P＜0.01, with model group than △ P＜0.05, △ △ P＜0.01
By table 18 as seen: after the rat modeling, arrive at the platform time obviously to prolong, the modeling success is described, sleep and consider each group of peace capsule and all can obviously shorten rat model and arrive at the platform time, significant difference is arranged with the model group ratio.It is the most obvious wherein to organize effect in a large number, and illustrating sleeps considers the memory function that the peace capsule can obviously improve rat model.
The influence of 8 pairs of stagnation of liver-QI rat model forced swimming dead times of experimental example
Getting body weight is 60 of 160g-180g rats, and grouping, modeling and administration are the same.Behind last administration 30min, rat put into the dark Plastic Drum that the depth of water is 35cm, after 25 ℃ of water temperatures are put into water 2min, begin to calculate the dead time in the 5min.The results are shown in Table 19.
Table 19 sleep to be considered the peace capsule to the stagnation of liver-QI rat model influence of forced swimming dead time (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Arrive at the platform time (s) |
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ?10 ?10 ?10 ?10 ?10 ?10 | Deng capacity such as capacity 8.10 0.98 2.95 8.86 | ??43.30±10.10 ??29.20±18.13* ??45.50±14.09△ ????46.00±16.06△△ ????38.50±18.15 ??53.50±20.69△△ |
With normal group than * P＜0.05, with model group than △ P＜0.05, △ △ P＜0.01
By table 19 as seen: after the rat modeling, non-swimming time obviously prolongs, and illustrates that modeling is successful, the obvious lengthening model rat forced swimming dead time of energy behind the application dormancy worry peace capsule, with the model group ratio significant differences is arranged.Illustrating sleeps considers the peace capsule certain sedation.
Experimental example 9 is slept and is considered the peace capsule hangs the transfixion time to the insufficiency of heart-QI model mice influence
Get body weight 18-22g male mice, be divided into normal group (waiting capacity), model group (waiting capacity), positive group (11.70g/kg) at random, sleep consider peace little (1.422g crude drug/kg), in (4.265g crude drug/g), a large amount of group (12.794g crude drug/g) (calculating by body surface area: be equivalent to clinical people and use 1,3 and 9 times of 10.935g crude drug every day).Under laboratory natural lighting condition, adopt small station platform water environment technology to deprive mice REM sleep.Model group mice small station platform diameter is 2cm, platform diameter side, matched group small station 6cm (mice can freely be slept), every day twice, each 30min, continuous 17 days, model group last lumbar injection pituitrin 0.2ml (50u/kg).Oral administration (0.2ml/10g body weight) according to dosage after modeling, continuous 4 days, 30min behind the last medicine hung on mice on the fixed stand upside down with cord.Record not when mice is movable occurs with the mice dead time in the stopwatch accumulative total 6min, the results are shown in Table 20 when motionless.
Table 20 sleep to be considered the peace capsule hangs the transfixion time to the insufficiency of heart-QI model mice influence (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Arrive at the platform time (s) |
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 11.70 1.42 4.27 12.79 | ??79.40±27.24 ??52.38±20.87* ??113.50±29.99△△ ????92.60±25.00△△ ????82.10±25.71△△ ????152.40±22.36△△ |
With normal group than * p＜0.05, with model group than △ △ P＜0.01
By table 20 as seen: after the mice modeling, the dead time obviously shortens, and with the normal group ratio, significant difference is arranged.Consider the peace capsule with sleeping after, each administration group obviously prolongs the insufficiency of heart-QI model mice and hangs the transfixion time, with the model group ratio significant difference is arranged.Illustrating sleeps considers the peace capsule certain sedation.
The influence of 10 pairs of insufficiency of heart-QI model mices of experimental example pentobarbital sodium induced hypnotic time
Get 60 of 18～22g mices, male and female half and half, be divided into normal group, model group, positive group at random, sleep consider peace little, in, heavy dose of group.Modeling is the same, after the modeling, presses table 5 dosed administration, successive administration 4 days, and behind last administration 30min, lumbar injection pentobarbital sodium 40mg/kg, the results are shown in Table 21 at the record mice sleep incubation period and the length of one's sleep from righting reflex loss to recovery.
Table 21 sleep to be considered the peace capsule to the influence of insufficiency of heart-QI model mice pentobarbital sodium induced hypnotic time (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Incubation period | Keep the phase |
| ??(min) | ??(min) | |||
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 11.70 1.42 4.27 12.79 | ??4.50±0.53 ??6.70±1.16 ??4.30±1.57△ ????4.60±2.27△ ????4.40±1.90△ ????4.00±1.41△ | ??42.30±5.38 ??33.70±6.12** ??52.90±11.00**△△ ????51.80±11.40*△△ ????54.90±6.52**△△ ????92.40±13.10**△△ |
With normal group than * P＜0.05, * * P＜0.01, with model group than △ P＜0.05, △ △ P＜0.01
By table 21 as seen: after the mice modeling, the prolongation of latency of sleep, keeping time phase obviously shortens, and with the normal group ratio, significant difference is arranged.After using the worry peace capsule of sleeping, obviously prolong the length of one's sleep of each administration group model mice, with the model group ratio significant differences arranged.Illustrating that capsule is pacified in the worry of sleeping and pentobarbital sodium has certain synergism.
Experimental example 11 is slept and is considered the influence of peace capsule to the memory of insufficiency of heart-QI model mice
Get 60 of 18～22g mices (arrive at platform time be no more than 120s), male and female half and half, grouping modeling administration is the same, trains twice continuously in Y type water maze in preceding 24 hours in the last administration, 30min behind the last medicine, the time that the mensuration mice is correctly arrived at platform the results are shown in Table 22.
The influence that table 22 dormancy worry peace capsule is remembered the insufficiency of heart-QI model mice (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Arrive at the platform time (s) |
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 11.70 1.42 4.27 12.79 | ??44.60±29.64 ??74.70±28.94* ??51.20±19.08△ ????43.00±28.85△ ????40.60±23.17△ ????24.50±26.40△△ |
With normal group than * P＜0.05, with model group than △ P＜0.05, △ △ P＜0.01
By table 22 as seen: after the mice modeling, arrive at the platform time obviously to prolong, hypomnesis with the normal group ratio, has significant difference.After using the worry peace capsule of sleeping, obviously shorten model mice and arrive at the platform time, significant difference is arranged with the model group ratio.Illustrating sleeps considers the function that the peace capsule can obviously improve the memory of model mice.
Experimental example 12 is slept and is considered the peace capsules to the influence of forced swimming dead time of insufficiency of heart-QI model mice
The screening body weight of learning from else's experience is 60 of 18-22g mices, male and female half and half, and grouping, modeling and administration are the same.Behind last administration 30min, mice is put into the dark Plastic Drum that the depth of water is 16cm, put into the dead time that begins to calculate 5min after water 2min mice adapts to, the results are shown in Table 23.
Table 23 sleep to be considered the peace capsule has the time to insufficiency of heart-QI model mice forced swimming influence (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Swimming time (s) |
| Normal group model group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 ??10 | Deng capacity such as capacity 11.70 1.42 4.27 12.79 | ??60.30±16.04 ??40.30±22.49* ??73.30±45.37△ ????65.50±35.24 ??69.50±41.32 ??107.50±59.66*△△ |
With normal group than * P＜0.05, with model group than △ P＜0.05, △ △ P＜0.01
By table 23 as seen: after the mice modeling, non-swimming time obviously shortens, and with the normal group ratio, significant difference is arranged.After using the worry peace capsule of sleeping, the non-swimming time of lengthening model mice, wherein a large amount of group effects are the most obvious, with the normal group ratio significant difference arranged, and with the model group ratio significant differences arranged.Illustrating sleeps considers the peace capsule certain sedation.
13 pairs of normal mouses of experimental example hang the influence of transfixion time
Get 50 of body weight 18～22g mices, male and female half and half, be divided into normal group (waiting capacity), positive group (11.70g/kg) at random, sleep consider the peace capsule little (1.422g crude drug/kg), in (4.265g crude drug/kg), a large amount of group (12.794g crude drug/kg), press body surface area and calculate, be equivalent to 1,3 and 9 times of clinical people's usefulness every day 10.935g crude drug.According to dosage oral administration (0.2ml/10g body weight) continuous 4 days, hangs on mice on the fixed stand with cord behind the 30min behind the last medicine upside down.Occur starting the mice dead time in the stopwatch accumulative total 6min when motionless writing time not when mice is movable, the results are shown in Table 24.
Table 24 sleep to be considered the peace capsule hangs the transfixion time to normal mouse influence (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Dead time (s) |
| Normal group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 | Deng capacity 11.70 1.42 4.27 12.79 | ??71.40±11.00 ??98.40±35.26* ??108.70±44.39* ??118.20±41.77** ??129.80±35.83** |
With normal group than * P＜0.05, * * P＜0.01
By table 24 as seen: the worry peace of sleeping capsule obviously prolongs mice; Hang the transfixion time, wherein a large amount of groups are the most obvious.With normal group than capable significant difference.Illustrating sleeps considers the peace capsule has certain sedation to normal mouse.
14 pairs of normal mouse pentobarbital sodiums of experimental example lure the influence of the different length of one's sleep
Getting body weight is 50 of 18～22g mices, male and female half and half, and grouping and dosage are the same, successive administration 4 days behind last administration 30min, is pressed 40mg/kg lumbar injection pentobarbital sodium, record mice incubation period and righting reflex loss the results are shown in Table 25 to the length of one's sleep of recovering.
Table 25 sleep to be considered the peace capsule to the normal mouse pentobarbital sodium influence of induced hypnotic time (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Incubation period | Keep the phase |
| ??(min) | ??(min) | |||
| Normal group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 | Deng capacity 11.70 1.42 4.27 12.79 | ??5.70±1.16 ??5.50±0.85 ??4.80±2.39 ??5.80±1.40 ??5.10±2.28 | ??40.10±8.44 ??53.00±12.62** ??56.10±11.79** ??57.50±5.76** ??72.40±9.31** |
With normal group than * P＜0.05, * * P＜0.01
By table 25 as seen: each administration group of the worry peace of sleeping capsule can obviously prolong holding time of normal mouse sleep, has compared significant differences with normal group.Illustrating sleeps considers the peace capsule has certain syngignoscism to normal mouse.
The influence of 15 pairs of normal mouse forced swimming dead times of experimental example
The screening body weight of learning from else's experience is 50 of 22～25g mices, and grouping and dosage are the same, and the ig administration is 4 days continuously, in last administration 30min, mice is put into the dark Plastic Drum that the depth of water is 16cm, puts into the dead time that begins to calculate 5min after water 2min adapts to.The results are shown in Table 26.
Table 26 sleep to be considered the peace capsule to the influence of normal mouse forced swimming dead time (x ± s)
| Group | Number of animals (n) | Dosage (g/kg) | Non-swimming time (s) |
| Normal group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | ??10 ??10 ??10 ??10 ??10 | Deng capacity 11.70 1.42 4.27 12.79 | ??64.90±20.54 ??91.50±32.39* ??71.30±27.91 ??91.70±36.84* ??105.60±54.12* |
With normal group than * P＜0.05
By table 26 as seen: sleep and consider the non-swimming time that the peace capsule can obviously prolong normal mouse, significant difference is arranged with the normal group ratio.Illustrating sleeps considers the peace capsule has certain sedation to normal mouse.
16 pairs of normal rats of experimental example are seized the influence of sexual assault behavior
Get 50 of 200～220g male rats, be divided into normal group (waiting capacity), positive group (8.10g/kg) at random, sleep consider peace little (0.984g crude drug/kg), in (2.952g crude drug/kg), heavy dose of group (8.856g crude drug/kg), press body surface area and calculate, be equivalent to 1,3 and 9 times of clinical people's usefulness every day 10.935g crude drug.Behind rat isolation and fasting 24h, a mice is put into cage, rat bites the mice cervical vertebra broken deadly positive.Respectively with administration before, 0.5h, 1h survey incubation period (calculating by 10 minutes) and the positive rate that rat is attacked after the administration, the results are shown in Table 27.
Table 27 sleep to be considered the peace capsule is seized the sexual assault behavior to normal rat influence (x ± s)
| Group | Dosage (g/kg) | Number of animals (n) | Incubation period (min) | Positive rate (%) | ||||
| Before the medicine | 0.5h behind the medicine | 1h behind the medicine | Before the medicine | 0.5h behind the medicine | 1h behind the medicine | |||
| Normal group positive group dormancy worry peace group (little) dormancy worry peace group (in) the worry peace group (greatly) of sleeping | Deng capacity 8.10 0.98 2.95 8.86 | ??10 ??10 ??10 ??10 ??10 | ??7.80±3.08 ??9.40±1.58 ??8.60±3.10 ??7.60±3.86 ??8.30±2.91 | ??7.70±3.23 ??9.50±1.58 ??9.10±2.85 ??8.80±2.69 ??8.50±2.72 | ??7.30±3.62 ??1000±0.00* ??9.50±1.58 ??9.10±1.91 ??10.00±0.00* | ??40％ ??20％ ??30％ ??30％ ??40％ | ??40％ ??10％ ??30％ ??2020％ ??30％ | ??40％ ??0％ ??30％ ??20％ ??0％ |
With normal group than * P＜0.05
By table 27 as seen: sleep and consider a large amount of groups of sexual assault behaviors of seizing that can obviously suppress normal rat of peace capsule, significant difference is arranged with the normal group ratio.Illustrating sleeps considers the peace capsule has certain sedation to normal rat.
Embodiment 1:Capsule of the present invention
Rhizoma Coptidis 45g Radix Rehmanniae 225g Radix Scutellariae 135g
Radix Paeoniae Alba 225g Fructus Schisandrae Chinensis 135g Semen Ziziphi Spinosae (stir-fry) 450g
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 8 times of amount 70% ethanol, reflux, extract, 2 times, and each 2 hours, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 8 times of water gagings, decoct each 2 hours 3 times, gradation filters, merging filtrate, and filtrate is concentrated into the clear paste that relative density is 1.10 (60 ℃ of heat are surveyed), adding ethanol makes and contains alcohol amount and reach 60%, stir evenly, cold preservation 24 hours filters, reclaim ethanol, be condensed into thick paste, be dried to driedly, be ground into fine powder.Get above-mentioned two kinds of extractum fine powders, add an amount of dextrin, micropowder silica gel, mixing adds an amount of ethanol and granulates, and drying incapsulates, and makes 1000.Oral, one time 3,3 times on the one.
Embodiment 2:Tablet of the present invention
Rhizoma Coptidis 35g Radix Rehmanniae 245g Radix Scutellariae 125g
Radix Paeoniae Alba 245g Fructus Schisandrae Chinensis 125g Semen Ziziphi Spinosae (stir-fry) 480g
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 6 times of amount 80% ethanol, reflux, extract, 3 times, and each 2 hours, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 10 times of water gagings, decoct each 1 hour 2 times, gradation filters, merging filtrate, and filtrate is concentrated into the clear paste that relative density is 1.10 (60 ℃ of heat are surveyed), add ethanol and make and contain alcohol amount and reach 50%, stir evenly cold preservation 24 hours, filter, reclaim ethanol, be condensed into thick paste, be dried to dried, be ground into fine powder, get above-mentioned two kinds of extractum fine powders and make 1000 in tablet according to conventional method.Oral, one time 3,3 times on the one.
Embodiment 3:Granule of the present invention
Rhizoma Coptidis 55g Radix Rehmanniae 210g Radix Scutellariae 145g
Radix Paeoniae Alba 205g Fructus Schisandrae Chinensis 145g Semen Ziziphi Spinosae (stir-fry) 420g
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 8 times of amount 60% alcohol, reflux, extract, 1 time, and each 1 hour, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 12 times of water gagings, decoct 2 hours time 1 time, get filtrate, filtrate is concentrated into relative density be 1.10 clear paste of (60 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 60%, stirs evenly, cold preservation 24 hours, filter, reclaim ethanol, be condensed into thick paste, be dried to driedly, be ground into fine powder.Get above-mentioned extractum fine powder, make granule according to conventional method.
Embodiment 4The discrimination method of this pharmaceutical composition:
Get this pharmaceutical composition 1g, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 30 minutes filters, and filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (12: 6: 3: 3: 1) is developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
Embodiment 5The discrimination method of this pharmaceutical composition:
1, gets the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with ethyl acetate-butanone-formic acid-water (5: 3: 1: 1) be developing solvent, launch, take out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
2, get this pharmaceutical composition 6g, add 60～90 ℃ petroleum ether 30ml, reflux 30 minutes filters, and medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, upper solution with petroleum ether (60-90 ℃)-Ethyl formate-formic acid (15: 5: 1) is developing solvent, launch, take out, dry, put under the ultra-violet lamp (254nm) and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 6The discrimination method of this pharmaceutical composition:
1, get this pharmaceutical composition 1g, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 30 minutes filters, and filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (12: 6: 3: 3: 1) is developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
2, get the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with ethyl acetate-butanone-formic acid-water (5: 3: 1: 1) be developing solvent, launch, take out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
3, get this pharmaceutical composition 6g, add 60～90 ℃ petroleum ether 30ml, reflux 30 minutes filters, and medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, upper solution with petroleum ether (60-90 ℃)-Ethyl formate-formic acid (15: 5: 1) is developing solvent, launch, take out, dry, put under the ultra-violet lamp (254nm) and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
4, get the medicinal residues after petroleum ether under the c item (60～90 ℃) extracts, volatilize petroleum ether, put in the tool plug conical flask, add methanol 40ml, close plug, supersound process 30 minutes filters, the filtrate evaporate to dryness, residue adds water 30ml makes dissolving, filters, and filtrate moves in the separatory funnel, add water saturated n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, and the ammonia (40ml strong aqua ammonia thin up to 100ml) saturated with n-butyl alcohol washs 3 times, each 10ml, discard washing liquid, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds dehydrated alcohol 2ml makes dissolving, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2) be developing solvent, launch, take out, dry, spray is with 5% vanillin sulphuric acid liquid, and it is clear to be heated to the speckle colour developing; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
5, get jujuboside A reference substance, add dehydrated alcohol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of jujuboside A reference substance solution under the embodiment 7, put respectively on same silica gel g thin-layer plate, upper strata liquid with n-butyl alcohol-glacial acetic acid-water (4: 1: 5) is developing solvent, launch, take out, dry, spray is with vanillin ethanol solution of sulfuric acid (get vanillin 2g add 10% ethanol solution of sulfuric acid 100ml dissolving), and it is clear to be heated to the speckle colour developing at 100 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 7The content assaying method of this medicament composition capsule agent:
Measure according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D).
With octadecylsilane chemically bonded silica is that potassium dihydrogen phosphate-acetonitriles filler: 0.05mol/L, 47: 53 are mobile phase, and wherein every 1000ml mobile phase contains sodium lauryl sulphate 1.7g; The detection wavelength is 265nm; Number of theoretical plate calculates by the berberine hydrochloride peak should be not less than 4000; It is an amount of that precision takes by weighing the berberine hydrochloride reference substance, uses 50% dissolve with methanol, makes the solution that every 1ml contains 0.025mg, shakes up, and promptly gets reference substance solution; Get the content under the content uniformity, porphyrize is got about 0.3g, the accurate title, decide, and puts in the tool plug conical flask, the accurate 50% methanol 50ml that adds, claim to decide weight, reflux 30 minutes is put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with 50% methanol, filter, get subsequent filtrate, filter, promptly get need testing solution with microporous filter membrane (0.45 μ m); Accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure, and every of this pharmaceutical composition contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 1.0mg.
The method of quality control of 8 medicament composition capsule agent of embodiment:
1, get this pharmaceutical composition 1g, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 30 minutes filters, and filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with benzene-ethyl acetate-methanol-isopropyl alcohol-strong ammonia solution (12: 6: 3: 3: 1) is developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
2, get the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with ethyl acetate-butanone-formic acid-water (5: 3: 1: 1) be developing solvent, launch, take out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
3, get this pharmaceutical composition 6g, add 60～90 ℃ petroleum ether 30ml, reflux 30 minutes filters, and medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, upper solution with petroleum ether (60-90 ℃)-Ethyl formate-formic acid (15: 5: 1) is developing solvent, launch, take out, dry, put under the ultra-violet lamp (254nm) and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
4, get the medicinal residues after petroleum ether under the c item (60～90 ℃) extracts, volatilize petroleum ether, put in the tool plug conical flask, add methanol 40ml, close plug, supersound process 30 minutes filters, the filtrate evaporate to dryness, residue adds water 30ml makes dissolving, filters, and filtrate moves in the separatory funnel, add water saturated n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, and the ammonia (40ml strong aqua ammonia thin up to 100ml) saturated with n-butyl alcohol washs 3 times, each 10ml, discard washing liquid, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds dehydrated alcohol 2ml makes dissolving, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2) be developing solvent, launch, take out, dry, spray is with 5% vanillin sulphuric acid liquid, and it is clear to be heated to the speckle colour developing; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
5, get jujuboside A reference substance, add dehydrated alcohol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw need testing solution and each 5 μ l of jujuboside A reference substance solution under the embodiment 7, put respectively on same silica gel g thin-layer plate, upper strata liquid with n-butyl alcohol-glacial acetic acid-water (4: 1: 5) is developing solvent, launch, take out, dry, spray is with vanillin ethanol solution of sulfuric acid (get vanillin 2g add 10% ethanol solution of sulfuric acid 100ml dissolving), and it is clear to be heated to the speckle colour developing at 100 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
6, measure according to high performance liquid chromatography (appendix VID of Chinese Pharmacopoeia version in 2000).
With octadecylsilane chemically bonded silica is that potassium dihydrogen phosphate-acetonitriles filler: 0.05mol/L, 47: 53 are mobile phase, and wherein every 1000ml mobile phase contains sodium lauryl sulphate 1.7g; The detection wavelength is 265nm; Number of theoretical plate calculates by the berberine hydrochloride peak should be not less than 4000; It is an amount of that precision takes by weighing the berberine hydrochloride reference substance, uses 50% dissolve with methanol, makes the solution that every 1ml contains 0.025mg, shakes up, and promptly gets reference substance solution; Get the content under the content uniformity, porphyrize is got about 0.3g, the accurate title, decide, and puts in the tool plug conical flask, the accurate 50% methanol 50ml that adds, claim to decide weight, reflux 30 minutes is put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with 50% methanol, filter, get subsequent filtrate, filter, promptly get need testing solution with microporous filter membrane (0.45 μ m); Accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure, and every of this pharmaceutical composition contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 1.0mg.
Claims (13)
1, a kind of Chinese medicine composition is characterized in that this pharmaceutical composition made by following raw material medicaments:
Rhizoma Coptidis 30-60 weight portion Radix Rehmanniae 200-250 weight portion Radix Scutellariae 120-150 weight portion
Radix Paeoniae Alba 200-250 weight portion Fructus Schisandrae Chinensis 120-150 weight portion
Semen Ziziphi Spinosae 400-500 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following raw material medicaments:
Rhizoma Coptidis 45 weight portion Radix Rehmanniae 225 weight portion Radix Scutellariaes 135 weight portions
The Radix Paeoniae Alba 225 weight portion Fructus Schisandrae Chinensis 135 weight portion Semen Ziziphi Spinosae (parched)s 450 weight portions.
3, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following raw material medicaments:
Rhizoma Coptidis 35 weight portion Radix Rehmanniae 245 weight portion Radix Scutellariaes 125 weight portions
The Radix Paeoniae Alba 245 weight portion Fructus Schisandrae Chinensis 125 weight portion Semen Ziziphi Spinosaes 480 weight portions.
4, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following raw material medicaments:
Rhizoma Coptidis 55 weight portion Radix Rehmanniae 210 weight portion Radix Scutellariaes 145 weight portions
The Radix Paeoniae Alba 205 weight portion Fructus Schisandrae Chinensis 145 weight portion Semen Ziziphi Spinosae (parched)s 420 weight portions.
5, as claim 1,2,3 or 4 described pharmaceutical compositions, it is characterized in that this pharmaceutical composition adds micropowder silica gel and dextrin is the molding adjuvant, dextrin: the ratio of micropowder silica gel is 1-3: 2-5.
6, preparation of drug combination method as claimed in claim 5 is characterized in that this method is:
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 6-10 and doubly measure 60-80% ethanol, reflux, extract, 1-3 time, and each 1-2 hour, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 8-12 times of water gaging, decoct each 1-3 hour 1-3 time, gradation filters, merging filtrate, and being concentrated into relative density 60 ℃ of filtrates is 1.10 clear paste, add ethanol and make and contain alcohol amount and reach 50-60%, stir evenly cold preservation 24 hours, filter, reclaim ethanol, be condensed into thick paste, be dried to driedly, be ground into fine powder, merge above-mentioned two kinds of fine powders, get this pharmaceutical composition, this pharmaceutical composition can be made into clinical acceptable forms.
7, preparation of drug combination method as claimed in claim 6 is characterized in that this method is:
Above Six-element, Rhizoma Coptidis, the Radix Paeoniae Alba, Fructus Schisandrae Chinensis add 8 times of amount 70% ethanol, reflux, extract, 2 times, and each 2 hours, merge alcohol extract, decompression recycling ethanol is condensed into thick paste, is dried to driedly, is ground into fine powder; Radix Rehmanniae, Radix Scutellariae, Semen Ziziphi Spinosae (parched) add 8 times of water gagings, decoct 3 times, and each 2 hours, gradation filtered, it is 1.10 clear paste that merging filtrate, filtrate are concentrated into relative density, adds ethanol and makes and contain the alcohol amount and reach 60%, stirs evenly, cold preservation 24 hours filters, and reclaims ethanol, is condensed into thick paste, be dried to driedly, be ground into fine powder, get above-mentioned two kinds of extractum fine powders, add an amount of dextrin, micropowder silica gel, mixing, add an amount of ethanol and granulate, drying incapsulates.
8,, it is characterized in that comprising in this method in the following discrimination method one or more as the method for quality control of claim 1,2,3 or 4 described pharmaceutical compositions:
A, get this pharmaceutical composition 1g, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 20-40 minute, filter, filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with 11-13: 5-7: 2-4: 2-4: the benzene-ethyl acetate of 1-2 ratio-methanol-isopropyl alcohol-strong ammonia solution is developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
B, get the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with 4-6: 2-4: 1-2: the ethyl acetate-butanone of 1-2 ratio-formic acid-water is developing solvent, launch, take out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get this pharmaceutical composition 6g, add 60～90 ℃ petroleum ether 30ml, reflux 20-40 minute, filter, medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, with 60-90 ℃, 12-18: 4-6: the 1-2 ratio the upper solution of petroleum ether-Ethyl formate-formic acid be developing solvent, launch, take out, dry, put under the ultra-violet lamp and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D, get under the c item medicinal residues behind 60-90 ℃ the Petroleum ether extraction, volatilize petroleum ether, put in the tool plug conical flask, add methanol 40ml, close plug supersound process 20-40 minute, filters, the filtrate evaporate to dryness, residue adds water 30ml makes dissolving, filters, and filtrate moves in the separatory funnel, add water saturated n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, uses the saturated ammonia scrubbing of n-butyl alcohol 3 times, each 10ml, discard washing liquid, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds dehydrated alcohol 2ml makes dissolving, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution; Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 30-50: 4-6: 8-12: the chloroform-ethyl acetate of 0.1-0.3 ratio-methanol-formic acid is developing solvent, launch, take out, dry, spray is with 5% vanillin sulphuric acid liquid, and it is clear to be heated to the speckle colour developing; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
E, get jujuboside A reference substance, add dehydrated alcohol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw need testing solution and each 5 μ l of jujuboside A reference substance solution under the d item, put respectively on same silica gel g thin-layer plate, with 3-5: 1-2: the upper strata liquid of the n-butyl alcohol-glacial acetic acid of 4-6 ratio-water is developing solvent, launch, take out, dry, spray is with the vanillin ethanol solution of sulfuric acid, and it is clear to be heated to the speckle colour developing at 100 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
9, method of quality control as claimed in claim 8 is characterized in that comprising in this method in the following discrimination method one or more:
A, get this pharmaceutical composition 1g, porphyrize is put in the tool plug conical flask, adds methanol 10ml, close plug, and supersound process 30 minutes filters, and filtrate is as need testing solution; Other gets Rhizoma Coptidis control medicinal material 50mg, shines medical material solution in pairs with legal system; Get the berberine hydrochloride reference substance again, add methanol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 2 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with 12: 6: 3: the benzene-ethyl acetate of 3: 1 ratios-methanol-isopropyl alcohol-strong ammonia solution was developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph and the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
B, get the baicalin reference substance, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw need testing solution and each 5 μ l of baicalin reference substance solution under a item, put respectively on same silica gel g thin-layer plate, with 5: 3: 1: the ethyl acetate-butanone of 1 ratio-formic acid-water was developing solvent, launched, and took out, dry, spray is with 1% ferric chloride alcoholic solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get this pharmaceutical composition 6g, add 60～90 ℃ petroleum ether 30ml, reflux 30 minutes filters, and medicinal residues are standby, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets the deoxyschizandrin reference substance, adds ethyl acetate and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw each 2 μ l of above-mentioned two kinds of solution, put respectively on same silica GF254 lamellae, upper solution with the petroleum ether-Ethyl formate-formic acid of 60-90 ℃, 15: 5: 1 ratios is developing solvent, launches, and takes out, dry, put under the ultra-violet lamp and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
D, get under the c item medicinal residues behind 60～90 ℃ the Petroleum ether extraction, volatilize petroleum ether, put in the tool plug conical flask, add methanol 40ml, close plug, supersound process 30 minutes filters, the filtrate evaporate to dryness, residue adds water 30ml makes dissolving, filters, and filtrate moves in the separatory funnel, add water saturated n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, uses the saturated ammonia scrubbing of n-butyl alcohol 3 times, each 10ml, discard washing liquid, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds dehydrated alcohol 2ml makes dissolving, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution; According to the thin layer chromatography test, draw each 3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 40: 5: 10: the chloroform-ethyl acetate of 0.2 ratio-methanol-formic acid was developing solvent, launched, and took out, dry, spray is with 5% vanillin sulphuric acid liquid, and it is clear to be heated to speckle colour developing; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
E, get jujuboside A reference substance, add dehydrated alcohol and make the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw need testing solution and each 5 μ l of jujuboside A reference substance solution under the d item, put respectively on same silica gel g thin-layer plate, upper strata liquid with the n-butyl alcohol-glacial acetic acid-water of 4: 1: 5 ratios is developing solvent, launch, take out, dry, spray is with the vanillin ethanol solution of sulfuric acid, and it is clear to be heated to the speckle colour developing at 100 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
10,, it is characterized in that comprising in this method following content assaying method as the method for quality control of claim 1,2,3 or 4 described pharmaceutical compositions:
According to high performance liquid chromatography; With octadecylsilane chemically bonded silica is that potassium dihydrogen phosphate-acetonitriles filler: 0.05mol/L, 47: 53 are mobile phase, and wherein every 1000ml mobile phase contains sodium lauryl sulphate 1.7g; The detection wavelength is 265nm; Number of theoretical plate calculates by the berberine hydrochloride peak should be not less than 4000; It is an amount of that precision takes by weighing the berberine hydrochloride reference substance, uses 50% dissolve with methanol, makes the solution that every 1ml contains 0.025mg, shakes up, and promptly gets reference substance solution; Get the content under the content uniformity, porphyrize is got about 0.3g, the accurate title, decide, and puts in the tool plug conical flask, the accurate 50% methanol 50ml that adds, claim to decide weight, reflux 20-40 minute, put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with 50% methanol, filter, get subsequent filtrate, filter, promptly get need testing solution with microporous filter membrane; Accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure, and every of this pharmaceutical composition contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 1.0mg.
11, method of quality control as claimed in claim 11 is characterized in that comprising in this method following content assaying method:
According to high effective liquid chromatography for measuring; With octadecylsilane chemically bonded silica is that potassium dihydrogen phosphate-acetonitriles filler: 0.05mol/L, 47: 53 are mobile phase, and wherein every 1000ml mobile phase contains sodium lauryl sulphate 1.7g; The detection wavelength is 265nm; Number of theoretical plate calculates by the berberine hydrochloride peak should be not less than 4000; It is an amount of that precision takes by weighing the berberine hydrochloride reference substance, uses 50% dissolve with methanol, makes the solution that every 1ml contains 0.025mg, shakes up, and promptly gets reference substance solution; Get the content under the content uniformity, porphyrize is got about 0.3g, the accurate title, decide, and puts in the tool plug conical flask, the accurate 50% methanol 50ml that adds, claim to decide weight, reflux 30 minutes is put cold, claim again to decide weight, supply the weight that subtracts mistake, shake up with 50% methanol, filter, get subsequent filtrate, filter, promptly get need testing solution with microporous filter membrane (0.45 μ m); Accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure, and the every measurement unit of this pharmaceutical composition contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 1.0mg.
12, as claim 1,2, the application of 3 or 4 described pharmaceutical compositions in the medicine of the insomnia of preparation treatment syndrome of hyperactivity of fire due to deficiency of YIN finding, dreaminess disease.
13, as claim 1,2,3 or 4 described pharmaceutical compositions have sedation in preparation, improve memory effect, application in the medicine of syngignoscism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100480876A CN100500182C (en) | 2004-06-15 | 2004-06-15 | Chinese medicinal composition, preparation and quality control thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100480876A CN100500182C (en) | 2004-06-15 | 2004-06-15 | Chinese medicinal composition, preparation and quality control thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1712034A true CN1712034A (en) | 2005-12-28 |
| CN100500182C CN100500182C (en) | 2009-06-17 |
Family
ID=35717942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100480876A Expired - Lifetime CN100500182C (en) | 2004-06-15 | 2004-06-15 | Chinese medicinal composition, preparation and quality control thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500182C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727646A (en) * | 2011-04-02 | 2012-10-17 | 张意明 | Medicine for treating insomnia |
| CN103063767A (en) * | 2012-12-21 | 2013-04-24 | 邯郸摩罗丹药业股份有限公司 | Quality standard of sanhuang dispersible tablets and detection method thereof |
| CN103630648A (en) * | 2013-10-15 | 2014-03-12 | 滨州医学院附属医院 | Method for detecting anti-infective drug |
| CN104208387A (en) * | 2014-09-29 | 2014-12-17 | 洛阳御平国生物科技有限公司 | Chinese medicinal formula for treating neurasthenia |
| CN105021762A (en) * | 2015-07-23 | 2015-11-04 | 河北中医学院 | Spine date seed water extract product rapid multi-information thin layer discriminating method |
| CN107621517A (en) * | 2016-07-14 | 2018-01-23 | 天津同仁堂集团股份有限公司 | A kind of detection method of Kechuanjing Syrup |
-
2004
- 2004-06-15 CN CNB2004100480876A patent/CN100500182C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727646A (en) * | 2011-04-02 | 2012-10-17 | 张意明 | Medicine for treating insomnia |
| CN102727646B (en) * | 2011-04-02 | 2014-04-16 | 张意明 | Medicine for treating insomnia |
| CN103063767A (en) * | 2012-12-21 | 2013-04-24 | 邯郸摩罗丹药业股份有限公司 | Quality standard of sanhuang dispersible tablets and detection method thereof |
| CN103630648A (en) * | 2013-10-15 | 2014-03-12 | 滨州医学院附属医院 | Method for detecting anti-infective drug |
| CN104208387A (en) * | 2014-09-29 | 2014-12-17 | 洛阳御平国生物科技有限公司 | Chinese medicinal formula for treating neurasthenia |
| CN105021762A (en) * | 2015-07-23 | 2015-11-04 | 河北中医学院 | Spine date seed water extract product rapid multi-information thin layer discriminating method |
| CN107621517A (en) * | 2016-07-14 | 2018-01-23 | 天津同仁堂集团股份有限公司 | A kind of detection method of Kechuanjing Syrup |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100500182C (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1876139A (en) | Medicinal preparation for treating children's fastidium, its preparation process and quality control method | |
| CN101040915A (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN1768854A (en) | Chinese medicinal capsule with spleen-supplementing, intestine-benefiting function | |
| CN1931205A (en) | Kindir leaf total flavone extract and its prepn and application | |
| CN1785293A (en) | Quality control method of heart pulse free flow oral preparation | |
| CN101062113A (en) | Milkwort extract, its preparation method and application | |
| CN1689596A (en) | Hypericum perforatum extract and its preparation process | |
| CN1712034A (en) | Chinese medicinal composition, preparation and quality control thereof | |
| CN1803787A (en) | Hypericum perforatum L. total flavone extracts, its preparation and application | |
| CN1813860A (en) | Dispersible tablet for clearing away heat of brain and heart and preparation process thereof | |
| CN1305512C (en) | Traditional Chinese medicine compound recipe for treating hyperplasia of mammary glands and preparation method thereof | |
| CN1843458A (en) | Chronic pharyngolaryngitis effervescence tablet and preparation method and its quality control method | |
| CN1907436A (en) | Medicinal composition for treating children's anorexia and preparation method thereof | |
| CN1608621A (en) | Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn | |
| CN1186051C (en) | 'Huajuhong' preparation and its preparing process | |
| CN1823975A (en) | Preparation for treating hysteritis and its quality control method | |
| CN1586612A (en) | Process for preparing granular powder for treating blood stasis disease and quality control method | |
| CN1903265A (en) | Traditional Chinese medicine composition for treating nycturia and its preparing method | |
| CN1857385A (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN1244336C (en) | Infantile antipyretic | |
| CN1657093A (en) | Preparation method of granular agent for raising leucocyte and its quality control method | |
| CN100344312C (en) | Prepn process of granule for treating children's hyperkinesia and its quality control method | |
| CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN101045077A (en) | Preparating method of oral solid preparation of fenugreek and its use | |
| CN1895605A (en) | Tangerine-seed phlegm and cough preparation, its making method and quality control |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160204 Address after: 710119, No. 70, West Avenue, new industrial zone, Changan District hi tech Development Zone, Shaanxi, Xi'an Patentee after: Shaanxi Buchang Hi-Tech Pharmaceutical Co.,Ltd. Address before: 100101 Chaoyang District Academy of Sciences Beijing south wind forest oasis F05-32C Patentee before: Chen Yongtai |
|
| CX01 | Expiry of patent term |
Granted publication date: 20090617 |